Neoprobe Corporation has announced that it has completed an exclusive license agreement with the University of California, San Diego (UCSD). The license affords Neoprobe the rights to a proprietary compound developed by researchers at UCSD.
The compound, which Neoprobe has designated Lymphoseek (TM), is being evaluated in clinical studies to determine its effectiveness in identifying lymphatic tissue in breast and in melanoma cancer patients.
David Bupp, Neoprobe’s president and CEO, said, “We are very pleased to have licensed Lymphoseek from UCSD. The initial clinical results from the Phase l clinical studies encouraged us to accelerate the Lymphoseek licensing activities. We will be working with the Phase I researchers to complete a submission package to the United States FDA to seek permission to begin the next phase of Lymphoseek clinical evaluation.”
Neoprobe develops and provides innovative surgical and diagnostic products that enhance patient care by meeting the critical decision making needs of healthcare professionals.